Evaluation of the safety and efficacy of sintilimab combined with chemotherapy as neoadjuvant therapy for locally advanced gastric/gastroesophageal junction adenocarcinoma: Short-term results of a multicenter phase II study.

作者
Qi Wei,Weidong Qiang,Bo Yeun Yang,Wanjing Chen,Huizhen Wang,Yongxiang Li
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:43 (16_suppl) 被引量:1
标识
DOI:10.1200/jco.2025.43.16_suppl.e16117
摘要

e16117 Background: Perioperative chemotherapy combined with gastrectomy and lymphadenectomy is the standard treatment for resectable locally advanced gastric/gastroesophageal junction adenocarcinoma (LAGC). Despite clinical trials confirming survival benefits of neoadjuvant chemotherapy (NACT) in resectable LAGC, many patients remain unresponsive, with low pathological complete response (pCR) rates. Sintilimab, a fully human, highly selective anti-PD-1 monoclonal antibody, blocks PD-1 interactions with PD-L1/PD-L2, eliciting a robust antitumor response. Combining sintilimab with NACT and radical resection may improve tumor downstaging and reduce distant recurrence risks. Methods: This study assessed the feasibility, efficacy, and safety of sintilimab combined with chemotherapy as neoadjuvant therapy for LAGC. Patients from three Chinese clinical centers with stage II (cT3-4N0M0 or cT1-3N1-3M0) or stage III (cT3-4aN1-3M0) LAGC were enrolled. Patients received sintilimab (200 mg, iv.gtt, Day 1, every 3 weeks) with XELOX chemotherapy (capecitabine: 1000 mg/m², oral, twice daily, Days 1-14, every 3 weeks; oxaliplatin: 130 mg/m², iv.gtt, Day 1, every 3 weeks) for three cycles. Preoperative imaging 3-4 weeks post-treatment evaluated efficacy and radical D2 resection eligibility. The primary endpoint was the pCR rate, with secondary endpoints including the major pathological response (MPR) rate, R0 resection rate, objective response rate (ORR), and disease control rate (DCR). Results: Between June 2023 and January 2025, 26 patients (10 gastric cancer, 13 gastroesophageal junction adenocarcinoma) were enrolled. As of January 20, 2025, 23 patients underwent radical surgery with an R0 resection rate of 100%. The pCR rate was 30.4% (7/23), and the MPR rate was 47.8% (11/23). ORR and DCR were 60.9% and 91.3%, respectively. Immune-related adverse events (irAEs) occurred in 4 patients (13.0%), including liver dysfunction (grade 3 and grade 1), hypothyroidism (grade 1), and dermatitis (grade 1). One patient experienced an anastomotic hemorrhage (4.3%), with no cases of anastomotic leakage or treatment-related death. Conclusions: The addition of sintilimab to neoadjuvant chemotherapy for LAGC, followed by radical surgery, demonstrated promising efficacy and a favorable safety profile. These results highlight a potential new strategy for neoadjuvant treatment of LAGC, warranting further validation through large-scale randomized clinical trials.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
迷路鞋子的应助被小熊维尼采纳,获得10
刚刚
楼马完成签到 ,获得积分10
1秒前
1秒前
爆裂鼓手完成签到,获得积分10
1秒前
顾矜的应助被麦当当采纳,获得10
1秒前
花栗鼠暴打芒果完成签到,获得积分10
1秒前
2秒前
活力的香发布了新的文献求助10
2秒前
2秒前
DW的应助被小黄采纳,获得10
2秒前
Otis完成签到,获得积分10
2秒前
3秒前
3秒前
愉快素阴完成签到,获得积分10
3秒前
Li完成签到,获得积分10
3秒前
3秒前
大个的应助被歪歪采纳,获得10
3秒前
体贴的含之完成签到,获得积分10
4秒前
ryu完成签到,获得积分10
4秒前
柠柠发布了新的文献求助10
4秒前
李健的应助被性感锅包肉采纳,获得10
4秒前
4秒前
墨玉完成签到,获得积分10
4秒前
冷酷秋柳发布了新的文献求助10
5秒前
Eason完成签到,获得积分10
5秒前
朱华彪完成签到,获得积分10
5秒前
ljs完成签到,获得积分10
5秒前
遇见发布了新的文献求助10
5秒前
6秒前
小海完成签到,获得积分10
6秒前
6秒前
7秒前
胡子木发布了新的文献求助10
7秒前
英姑的应助被Elowen采纳,获得30
7秒前
7秒前
8秒前
SARON完成签到 ,获得积分10
8秒前
Leon完成签到,获得积分10
8秒前
慕青的应助被aaa采纳,获得10
8秒前
熊猫小肿完成签到,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180586
求助须知:如何正确求助?哪些是违规求助? 9570581
关于积分的说明 21813457
捐赠科研通 7776777
什么是DOI,文献DOI怎么找? 3433294
关于科研通互助平台的介绍 2557547
邀请新用户注册赠送积分活动 2479253